Spero Therapeutics
SPRO
47 hedge funds and large institutions have $21.3M invested in Spero Therapeutics in 2025 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 11 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
27% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 11
7% more funds holding
Funds holding: 44 → 47 (+3)
0.29% more ownership
Funds ownership: 19.82% → 20.1% (+0.29%)
34% less capital invested
Capital invested by funds: $32.1M → $21.3M (-$10.9M)
45% less call options, than puts
Call options by funds: $195K | Put options by funds: $355K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.36M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$331K |
| 3 |
IFO
Intrepid Family Office
Sarasota,
Florida
|
+$242K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$235K |
| 5 |
SC
Shay Capital
New York
|
+$140K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.48M |
| 2 |
MCM
Monimus Capital Management
Woodbridge,
New Jersey
|
-$902K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$455K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$327K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$228K |
SPRO Hedge Fund Activity: Q3 2025 in Review
47 of the 7,645 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q3 2025, worth a combined $21.3M — down 34% from $32.1M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new SPRO positions and 11 closed out — a net gain of 3 holders — while 12 added to existing stakes and 6 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $1.36M. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $1.48M sold.
- 47 institutional investors held Spero Therapeutics (SPRO) as of Q3 2025, up from 44 in Q2 2025.
- Funds reported $21.3M of Spero Therapeutics stock for Q3 2025, down 34% quarter-over-quarter.
- 14 funds opened new Spero Therapeutics positions in Q3 2025 and 11 closed out, a net change of +3 holders.
- The largest Spero Therapeutics buyer in Q3 2025 was Renaissance Technologies, an estimated $1.36M added.
- The largest Spero Therapeutics seller in Q3 2025 was Schonfeld Strategic Advisors, an estimated $1.48M sold.
Based on aggregated 13F filings for Q3 2025.